Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis

Marco Capobianco; Simona Malucchi; Stefano Ulisciani; Carmen Fava; Giovanna Rege Cambrin; Luigina Avonto; Giuseppe Saglio; Antonio Bertolotto

doi:10.1007/s10072-008-0934-1

Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis

Neurol Sci. 2008 Jun;29(3):185-7. doi: 10.1007/s10072-008-0934-1. Epub 2008 Jul 9.

Authors

Marco Capobianco¹, Simona Malucchi, Stefano Ulisciani, Carmen Fava, Giovanna Rege Cambrin, Luigina Avonto, Giuseppe Saglio, Antonio Bertolotto

Affiliation

¹ Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica, Aou S Luigi Gonzaga, Regione Gonzole 10, Orbassano TO, Italy.

PMID: 18612769
DOI: 10.1007/s10072-008-0934-1

Abstract

Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known. We describe a case wherein the patient developed t-AML 11 months after mitoxantrone had been discontinued. The patient was treated by polychemotherapy and autologous bone marrow transplantation with complete recovery of t-AML and stabilization of the neurological disease.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow Transplantation
DNA Topoisomerases, Type II / metabolism
Dose-Response Relationship, Drug
Enzyme Inhibitors / adverse effects
Female
Humans
Immunosuppressive Agents / adverse effects*
Leukemia, Myeloid, Acute / chemically induced*
Leukemia, Myeloid, Acute / physiopathology
Mitoxantrone / adverse effects*
Multiple Sclerosis / drug therapy*
Remission Induction
Topoisomerase II Inhibitors
Treatment Outcome

Substances

Enzyme Inhibitors
Immunosuppressive Agents
Topoisomerase II Inhibitors
Mitoxantrone
DNA Topoisomerases, Type II